Millennium Pharmaceuticals Limited

Portola Pharmaceuticals, Inc.

Millenium Pharmaceuticals, Inc.

Craig Grant

James P Kanter

Graeme Langlands

Robert M Scarborough

Xiaoming Zhang

Wolin Huang

Mukund Mehrotra

Carroll Scarborough, Legal Representative

Hilary Cannon

The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I. 

Pharmaceutical salts and polymorphs of a factor Xa inhibitor

The present invention provides methods for preventing or treating a condition characterized by undesired thrombosis in a mammal using a crystalline polymorph form of a maleate salt of a compound of Formula I that has activity against mammalian factor Xa. 

Methods of using crystalline forms of a salt of a factor Xa inhibitor

The present invention provides novel sulfonylurea compounds of formula (I) and pharmaceutically acceptable derivatives and polymorph and amorphous forms thereof. The compounds in their various forms are effective platelet ADP receptor inhibitors and may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of cardiovascular diseases, particularly those diseases related to thrombosis. The invention also provides a method for preparing such compounds and forms and for preventing or treating thrombosis and thrombosis related conditions in a mammal comprising the step of administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or forms thereof.

[4-(6-halo-7-substituted-2,4-dioxo-1,4-dihydro-2H-quinazolin-3-yl)-phenyl]-5-chloro-thiophen-2-yl-sulfonylureas and forms and methods related thereto

Growing community of inventors

Burwell, United Kingdom

Craig Grant